VEGF Trap vs. Lucentis: the test begins

Article

VIEW 2, a Phase III trial evaluating the efficacy and safety of VEGF Trap (afilbercept; Regeneron) versus Lucentis (ranibizumab; Novartis) administered by intravitreal injection for the treatment of neovascular age-related macular degeneration (wet AMD), has dosed its first patient.

VIEW 2, a Phase III trial evaluating the efficacy and safety of VEGF Trap (afilbercept; Regeneron) versus Lucentis (ranibizumab; Novartis) administered by intravitreal injection for the treatment of neovascular age-related macular degeneration (wet AMD), has dosed its first patient.

The VIEW 2 trial, which will enrol approximately 1200 patients in up to 200 centres around Europe, Japan, Asia Pacific and Latin America, is designed to demonstrate non-inferiority of VEGF Trap with Lucentis. It is the second of two Phase III trials, the first of which (VIEW 1) began enrolling patients in the US and Canada in August 2007. Both trials have the same study design and endpoints.

Patients in the trial will be randomized to receive 0.5 mg and 2.0 mg of VEGF Trap at four-week intervals and 2.0 mg at eight-week intervals, with an additional dose of 2.0 mg at week four; ranibizumab patients will receive 0.5 mg doses at four-week intervals. Following one year of treatment, patients will continue to receive treatment at intervals between four and 12 weeks for a further year.

The Phase II trial achieved both primary and secondary endpoints of reduction in retinal thickness and improvement in visual acuity after 12 weeks of treatment with VEGF Trap. The primary endpoint of the Phase III trial is to compare vision maintenance at one year from baseline between patients treated with VEGF Trap in comparison to patients treated with ranibizumab. Initial results from VIEW 2 are expected in 2011.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.